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Introduction {#sec1}
============

Mutations in *LDLR* (encoding LDL receptor, LDLR), often heterozygous, underlie most cases of familial hypercholesterolemia (FH), which predisposes to premature cardiovascular disease due to marked elevation of plasma levels of lipids, in particular low-density lipoprotein cholesterol (LDL-C) ([@bib7]). Besides diet control and physical activity, FH patients are treated with statins, a class of drugs that inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase and hence reduce cholesterol synthesis in the liver ([@bib16]). Statins also increase LDLR protein levels in hepatocytes and LDL-C clearance from plasma. Because of these properties, statins are used to treat FH patients and also patients with non-familial hypercholesterolemia. However, statins fail to reduce plasma LDL-C adequately in the majority of these patients for prevention of cardiovascular events ([@bib8], [@bib28]), and a proportion of patients suffers from significant adverse effects ([@bib14], [@bib36]).

Importantly, FH can be caused by mutations in other genes besides *LDLR*, including gain-of-function mutations in proprotein convertase subtilisin/kexin type 9 (PCSK9) ([@bib33]). This observation led to the subsequent identification of PCSK9 as an extracellular protein responsible for the internalization and degradation of surface LDLR in hepatocytes ([@bib24]). Interestingly, PCSK9 is induced by statins, and activates a negative feedback loop that controls LDLR expression and consequently restrains the efficacy of statins ([@bib15]). The latter may account for the limited efficacy or even loss of efficacy of statins in some patients, and has suggested that PCSK9 modulation could be of therapeutic relevance. In this regard, clinical trials with anti-PCSK9 therapy (in the form of monoclonal antibodies) have shown potent lowering effects on LDL-C and good tolerance, creating a tremendous interest in this approach as an alternative medication for hypercholesterolemia ([@bib29], [@bib30]). Besides the potential paradigm shift in FH treatment, these findings imply that interfering with additional components of the LDLR degradation pathway (besides PCSK9) may provide alternative therapeutic avenues for hypercholesterolemia.

Despite the exciting developments with PCSK9 antibodies, a relevant caveat for further exploration of new therapies (new drugs or new formulations) for FH (and also other genetic liver diseases) is the lack of easily accessible and bona fide in vitro and in vivo models for preclinical testing. In vitro models for FH are mostly based on patient-derived hepatocytes from liver biopsy ([@bib11]), which have limited accessibility and cannot be expanded in culture. In vivo models including the hyperlipidemic rabbit, the rhesus macaque, and the *Ldlr* knockout mouse, have the limitation of not fully recapitulating human hepatocyte function ([@bib6]). Patient-specific induced pluripotent stem cells (iPSCs) can provide an unlimited source of differentiated cell types including hepatocytes (iHeps) that can be used for in vitro and in vivo studies ([@bib17], [@bib37]). This approach combined with the transplantation into immunodeficient mice may help overcome existing problems in modeling FH in vitro and in vivo ([@bib10], [@bib12], [@bib23]). Several groups have generated FH iPSCs that harbor mutations in *LDLR* ([@bib11], [@bib26], [@bib27]) or *PCSK9* ([@bib32]) and have tested the ability of the derived iHeps to mimic the disease phenotype and respond to statins in vitro. However, there are no reports so far testing the effect of anti-PCSK9 therapies on FH iPSC-derived iHeps in vitro, or in vivo disease modeling and drug testing with FH iHeps transplanted into appropriate animal models.

Here, we report that FH iHeps derived from patient-specific and genetically engineered FH iPSCs can be used to test the efficacy of two well-known medications for lowering LDL-C, statins and PCSK9 antibodies, not only in vitro but also in vivo, by engrafting FH iHeps into the liver of immunodeficient mice knockout for *Ldlr*. With these assays, we have confirmed clinical observations of higher potency of PCSK9 antibodies compared with statins for treating FH ([@bib29]), indicating the potential of our model for further drug discovery and preclinical testing of experimental therapies.

Results {#sec2}
=======

Generation of a Panel of Patient-Specific and Genetically Engineered FH iPSCs for In Vitro and In Vivo Studies {#sec2.1}
--------------------------------------------------------------------------------------------------------------

We selected a family with clinical FH due to heterozygous duplication of "TGCTGGC" (c.2108_2114dup, p.Ala705fsX14) in exon 14 of *LDLR* ([@bib20]) ([Figures 1](#fig1){ref-type="fig"}A and 1B), which results in a premature stop codon. Using urinary cells as a donor cell source ([@bib4], [@bib46]) and episomal vectors as the reprogramming method ([@bib41]), we generated integration-free iPSCs from the two affected sisters (FH-1 and FH-2) and the healthy sister (wild-type, WT) ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A); individual clones for each person were selected for further study. The resulting cell lines were fully pluripotent as shown by immunofluorescence (SSEA-4 and NANOG), RT-qPCR (*OCT4*, *SOX2*, *NANOG*, and *TERT*), DNA demethylation of the *NANOG* proximal promoter, and the formation of teratomas in immunocompromised mice ([Figures S1](#mmc1){ref-type="supplementary-material"}B--S1E). Moreover, their karyotypes were normal ([Figure S1](#mmc1){ref-type="supplementary-material"}C) and after serial passaging there was no remnant of the episomal vectors employed for reprogramming, as tested by PCR ([Figure S1](#mmc1){ref-type="supplementary-material"}F). We also confirmed the *LDLR* mutation and the reduced expression of LDLR protein in the two FH iPSC clones by sequencing and western blotting, respectively ([Figures 1](#fig1){ref-type="fig"}B and 1C).

Next, because variations in the genetic background among iPSCs can be a confounding factor for in vitro disease modeling ([@bib34]), we used zinc-finger nucleases (ZFNs) ([@bib25]) targeting exon 4 of *LDLR* ([Figure S2](#mmc1){ref-type="supplementary-material"}A) to create a panel of isogenic *LDLR* knockout iPSCs in a previously generated and well-characterized urinary iPSC clone from an unaffected individual ([@bib46]). This produced two biallelic knockout clones and 27 monoallelic knockout clones out of 214 clones screened by sequencing ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Of the resulting cell lines, we selected one monoallelic knockout (+/−) clone, one biallelic knockout (−/−) clone, and the unmodified control (+/+) as a panel for further study ([Figure 1](#fig1){ref-type="fig"}D). These isogenic iPSCs retained pluripotency, displayed normal karyotypes, and expressed LDLR levels according to their genotypes ([Figures 1](#fig1){ref-type="fig"}C, [S2](#mmc1){ref-type="supplementary-material"}C, and S2D). Therefore, we have generated two complementary panels of iPSCs for studying FH mechanisms and performing drug screening.

PCSK9 Antibodies Show Stronger LDL-Lowering Ability than Statins in FH iHeps {#sec2.2}
----------------------------------------------------------------------------

We differentiated our panel of patient-specific and isogenic FH iPSCs into functional iHeps with a previously reported three-step protocol ([@bib19]). After 17 days of differentiation, iHeps with equivalent morphology to human hepatocytes appeared ([Figure 1](#fig1){ref-type="fig"}E). These iHeps displayed markers of primary hepatocytes including asialoglycoprotein receptor (ASGPR) and α1-antitrypsin (A1AT) ([Figure 1](#fig1){ref-type="fig"}E), stored glycogen and lipids, secreted albumin and urea, and had the ability to metabolize rifampicin via the cytochrome P450 pathway ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3E). Importantly, the efficiency of iHep differentiation between patient-specific and isogenic FH iPSCs was comparable, as measured by analyzing the population of ASGPR^+^ cells by flow cytometry ([Figure 1](#fig1){ref-type="fig"}F).

To reveal the main phenotypic feature of FH (inability to uptake plasma LDL-C by hepatocytes) in vitro, we incubated iHeps from the various iPSC lines with 5 μg/mL fluorescently labeled LDL for 3.5 hr, followed by co-staining with hepatocyte nuclear factor 4α (HNF4A) to confirm the identity of the iHeps. As expected, WT and +/+ iHeps showed high---and rather comparable---LDL uptake while this was significantly impaired in FH-1, FH-2, and +/− iHeps, and completely abolished in −/− iHeps ([Figure 2](#fig2){ref-type="fig"}A). Similar results were obtained when LDL capture was measured using flow cytometry and normalized by the number of ASGPR^+^ cells ([Figure 2](#fig2){ref-type="fig"}B, left panel). With the same assay, we also observed that 10 μM simvastatin elevated LDL uptake in FH-1 iHeps and +/− iHeps ([Figure 2](#fig2){ref-type="fig"}B, left panel), and more modestly in WT and +/+ iHeps. However, there was only marginal basal LDL uptake, without elevation with simvastatin, in −/− iHeps ([Figure 2](#fig2){ref-type="fig"}B, left panel). In addition, we measured total cholesterol (TC) and apolipoprotein B (APOB) secretion (an indirect measure of LDL secretion) ([@bib11]) in our panel of iHeps. TC and APOB were increased in FH-1 iHeps compared with WT, and in +/− and −/− iHeps compared with +/+ iHeps ([Figure 2](#fig2){ref-type="fig"}B, middle and right panels). On the other hand, 10 μM simvastatin reduced TC and APOB levels in iHeps from all tested iHeps but in particular in +/−, −/−, and FH-1 iHeps ([Figure 2](#fig2){ref-type="fig"}B, middle and right panels).

In the clinic, the inefficiency of statins in reducing LDL-C in some FH patients is partly due to increased PCSK9 expression, as this promotes LDLR degradation ([@bib24]). To confirm whether PCSK9 is also upregulated by statins in iHeps in vitro, we performed western blotting of FH-1 and WT iHeps untreated or treated with simvastatin, observing that the treatment increases PCSK9 expression ([Figure 2](#fig2){ref-type="fig"}C). We then developed a 48-well-based assay to compare systematically the effect of different concentrations of statins and PCSK9 antibodies on LDL uptake in iHeps. In isolation, PCSK9 antibodies were more potent than simvastatin in inducing LDL uptake in healthy and heterozygous FH iHeps, and their combination did not increase it further ([Figure 2](#fig2){ref-type="fig"}D). Neither simvastatin nor PCSK9 antibodies had any effect on LDL uptake in −/− iHeps ([Figure S3](#mmc1){ref-type="supplementary-material"}F). These in vitro results reproduce clinical observations showing that PCSK9 antibodies are a remarkable substitute for statins in treating heterozygous FH patients but are ineffective for homozygous FH patients ([@bib35]).

Engrafted iHeps Reduce Plasma LDL-C Levels in an FH Chimeric Mouse Model {#sec2.3}
------------------------------------------------------------------------

To further expand our iHep platform and perform drug testing in vivo, we crossed *Ldlr*^*−*/*−*^ mice ([@bib18]) with *Rag2*^*−*/*−*^/*Il2rg*^*−*/*−*^ mice, and so generated triple-knockout *LRG* mice ([Figure 3](#fig3){ref-type="fig"}A). *LRG* mice lack an effective adaptive immune system, allowing the transplantation of human iHeps into an LDLR null background without rejection. To demonstrate this, we engrafted iHeps from FH iPSCs into *LRG* mice via intrasplenic injection. To improve the repopulation efficiency, we exposed mice to 3 Gy of γ-ray radiation 24 hr prior to engraftment to induce moderate liver injury and so enable proliferation of the engrafted iHeps. In addition, we suspended the injected iHeps in 50% Matrigel to provide a microenvironment that facilitates migration into the liver from the spleen ([Figure 3](#fig3){ref-type="fig"}B). The evidence of liver repopulation with iHeps in *LRG* mice was assessed by immunohistochemical staining for LDLR, human albumin (hALB), and human nuclear antigen (hNA) ([Figures 3](#fig3){ref-type="fig"}C and 3D). To determine iHep engraftment efficiency, we first stained chimeric mouse liver sections with hALB antibodies and then scanned the whole sections to quantify hALB^+^ areas ([Figures 3](#fig3){ref-type="fig"}E, 3F, and [S4](#mmc1){ref-type="supplementary-material"}A). With this strategy, we were able to assess iHep engraftment efficiency in multiple lobules and lobes rather than in small-area images. All tested iHeps showed significant repopulation in *LRG* mouse liver 3 weeks after transplantation, based on hALB staining, although with slight variations in efficiency (ranging from ∼5% to ∼10%) ([Figure 3](#fig3){ref-type="fig"}G). Because hALB is a secreted protein and dispersion could influence the assessment, we also used hNA to calculate iHep engraftment efficiency, which showed a moderately higher value than with hALB (∼15% on average for different iHeps) ([Figure 3](#fig3){ref-type="fig"}H). No evidence of hALB^+^ or hNA^+^ cells was observed in *LRG* mouse liver engrafted with vehicle ([Figures 3](#fig3){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}A). Likewise, there was no positive signal in the spleen of animals injected with iHeps ([Figure S4](#mmc1){ref-type="supplementary-material"}B), demonstrating that transplanted cells do not engraft there after injection.

Fed a normal diet, *LRG* mice engrafted with +/+ iHeps had lower, but not statistically significant, levels of plasma LDL-C (n = 6, 57.9 ± 3.1 mg/dL) compared with vehicle (n = 4, 112.7 ± 20.6 mg/dL) 3 weeks after transplantation, while +/− iHeps (n = 4, 72.5 ± 12.0 mg/dL) and FH-1 iHeps (n = 5, 70.1 ± 12.7 mg/dL) were less effective ([Figure 3](#fig3){ref-type="fig"}I, left panel). As expected, −/− iHeps had no effect on LDL-C clearance (n = 6, 119.6 ± 6.9 mg/dL) compared with vehicle ([Figure 3](#fig3){ref-type="fig"}I, left panel). We then fed *LRG* mice with a high-fat, high-cholesterol (HFHC) diet to see whether this magnifies differences in LDL-C lowering after iHep transplantation. *LRG* mice showed around a 3-fold increase in LDL-C plasma after 1 week on HFHC diet ([Figure 3](#fig3){ref-type="fig"}I, right panel). Under this condition, transplanted +/+ iHeps (n = 5, 275.1 ± 19.0 mg/dL), and to a lesser extent +/− iHeps (n = 6, 439.3 ± 35.6 mg/dL) and FH-1 iHeps (n = 6, 414.7 ± 42.0 mg/dL), significantly downregulated plasma LDL-C levels compared with vehicle (n = 6, 606.7 ± 27.7 mg/dL) or −/− iHeps (n = 6, 617.3 ± 22.8 mg/dL) (p \< 0.01, [Figure 3](#fig3){ref-type="fig"}I, right panel). To assess the long-term effects of engrafted iHeps compared with primary human hepatocytes (pHH), we tested LDL-C levels 12 weeks after transplantation of +/+ iHeps and pHH into *LRG* mice fed with HFHC diet, observing notable and rather comparable plasma LDL-C clearance in both cases compared with vehicle (p \< 0.05, [Figure 3](#fig3){ref-type="fig"}J). The evidence of engrafted cells at this time point was assessed by staining for hALB and hNA in liver sections ([Figure 3](#fig3){ref-type="fig"}K). Overall, these experiments demonstrate that transplantation of LDLR-competent but not LDLR null iHeps promotes plasma LDL-C clearance in *LRG* mice.

Alirocumab Shows Stronger LDL-Lowering Ability than Statins in Chimeric *LRG* Mice {#sec2.4}
----------------------------------------------------------------------------------

We then used HFHC diet to assess the effect of PCSK9 antibodies compared with statins on iHeps engrafted into *LRG* mice ([Figure 4](#fig4){ref-type="fig"}A). Importantly, we used a clinical-grade formulation of PCSK9 monoclonal antibodies, alirocumab (Sanofi and Regeneron Pharmaceuticals), which has completed phase III clinical trials ([@bib29]) and was approved by the Food and Drug Administration in July 2015 as a cholesterol-lowering drug. Alirocumab at 10 mg/kg/week enhanced plasma LDL-C clearance by engrafted +/− iHeps ([Figure 4](#fig4){ref-type="fig"}B; n = 3, percentage reduction from baseline 50.06% ± 7.38%, p \< 0.05 compared with +/− iHeps alone) and FH-1 iHeps ([Figure 4](#fig4){ref-type="fig"}C; n = 3, percentage reduction from baseline 61.29% ± 10.80%, p \< 0.05 compared with FH-1 iHeps alone) 21 days after treatment. Simvastatin at 10 mg/kg/day also reduced LDL-C clearance by engrafted +/− iHeps (n = 3, percentage reduction 33.37% ± 10.55%, p \> 0.05 compared with iHeps alone) and FH-1 iHeps (n = 5, percentage reduction 28.39% ± 9.55%, p \> 0.05 compared with iHeps alone), but less significantly than alirocumab, and their combination was not synergistic ([Figures 4](#fig4){ref-type="fig"}B and 4C). Moreover, in chimeric mice engrafted with −/− iHeps, alirocumab alone had no effect, while simvastatin alone or combined with alirocumab had only a modest effect on LDL-C clearance ([Figure 4](#fig4){ref-type="fig"}D). This moderate effect of simvastatin (alone or in combination) on engrafted −/− iHeps is likely due to inhibition of HMG-CoA reductase ([@bib16]). Notably, the observed percentage reduction of plasma LDL-C with alirocumab in *LRG* mice engrafted with +/− iHeps or FH-1 iHeps is similar to that reported in human studies ([@bib29], [@bib30]). These results show the potential utility of *LRG* mice engrafted with FH iHeps for preclinical testing of novel drugs for FH.

Improvement of Endothelium-Dependent Vasodilation in Chimeric *LRG* Mice by Alirocumab and Statins {#sec2.5}
--------------------------------------------------------------------------------------------------

One consequence of FH is the accelerated development of atherosclerosis on the arterial wall ([@bib39]), but we did not observe any obvious development of atherosclerotic lesions (assessed by oil red O staining) in our *LRG* mice fed with HFHC diet (data not shown). This is likely due to their compromised immune system and the relatively short period on the HFHC diet. Impaired endothelial function is an early indicator of atherosclerosis in children and young adults with FH ([@bib40]), which manifests as reduced flow-mediated endothelium-dependent vasodilation (EDV) and increased proinflammatory gene expression, while EDV in response to glyceryl trinitrate in these patients is comparable with that in control subjects ([@bib1]). We found that EDV induced by cumulative concentrations of acetylcholine (ACh) was significantly improved in aortic rings of *LRG* mice engrafted with +/+ iHeps compared with *LRG* mice engrafted with FH-1 iHeps, +/− iHeps, or −/− iHeps (p \< 0.01, [Figure 5](#fig5){ref-type="fig"}A). However, endothelium-independent vasodilation induced by sodium nitroprusside was similar in endothelium-denuded aortic rings from all *LRG* groups ([Figure 5](#fig5){ref-type="fig"}B). Alirocumab at 10 mg/kg/week improved EDV significantly in *LRG* mice engrafted with +/− (p \< 0.01) or FH-1 iHeps (p \< 0.05, [Figures 5](#fig5){ref-type="fig"}C and 5D), while there was no effect on *LRG* mice engrafted with −/− iHeps or vehicle ([Figures 5](#fig5){ref-type="fig"}E and 5F). In contrast, 10 mg/kg/day simvastatin improved EDV in aortas of all groups ([Figures 5](#fig5){ref-type="fig"}C--5F), supporting the knowledge that the vasoprotective effect of simvastatin is partially independent of LDLR status ([@bib38]). Moderate synergistic effect of simvastatin and alirocumab on EDV in aortic rings was observed in *LRG* mice engrafted with +/− iHeps or FH-1 iHeps, but not −/− iHeps or vehicle ([Figures 5](#fig5){ref-type="fig"}C--5F). Simvastatin or alirocumab did not have any effect on sodium nitroprusside-induced relaxation in aortic rings from *LRG* mice engrafted with all groups of iHeps or vehicle ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5D). Furthermore, RT-qPCR of aorta samples from *LRG* mice engrafted with +/− iHeps showed that treatment with alirocumab, simvastatin, or their combination significantly reduced the expression of cytokines, chemokine receptors, and adhesion molecules related to vascular inflammation ([Figure S5](#mmc1){ref-type="supplementary-material"}E). Therefore, EDV in aortas is a good readout for monitoring the consequences of FH in *LRG* mice engrafted with FH iHeps, and is responsive to treatment with PCSK9 antibodies or statins.

Discussion {#sec3}
==========

Patient-specific iPSCs can be differentiated into disease-relevant cells, thus providing an unlimited source of human cells for in vitro studies ([@bib17]). Using this disease-in-a-dish approach, multiple human conditions including liver diseases have been modeled ([@bib22], [@bib27], [@bib44]). In this study, we have employed patient-specific FH iPSCs and genetically engineered isogenic FH iPSCs to create a platform for in vitro and in vivo drug testing of LDL-C-lowering therapies.

Several groups have previously reported FH iPSCs harboring mutations in *LDLR* and *PCSK9* and the ability of the derived iHeps to increase LDL uptake in vitro upon treatment with statins ([@bib11], [@bib26], [@bib32]). Our work has focused on testing therapies for FH, in particular anti-PCSK9 antibodies, in vitro and in vivo using FH iHeps, although this has been previously studied in vitro using pHH ([@bib45]). Likewise, FH disease modeling with isogenic iPSCs, which allow healthy versus diseased comparison of iHeps that share the same genetic background, had not been described beforehand. The addition of isogenic iPSCs may overcome the shortcomings of using a small number of patient-specific iPSCs and clones for identifying FH phenotypes in this study. Consistent with previous studies using FH iHeps ([@bib11], [@bib26], [@bib32]), our in vitro experiments confirm that statins increase LDL uptake in FH iHeps and also demonstrate a concomitant reduction in TC and APOB level. To facilitate the systematic screening of LDL-C-lowering medications with FH iHeps, we designed a 48-well assay based on labeled LDL capture. This assay showed higher efficacy in increasing LDL capture of PCSK9 antibodies compared with statins, and in the future may prove useful for identifying new candidate drugs for treating FH through systematic screening. In this regard, our assay may be adaptable to 96-well plates through further optimization.

Human liver chimeric mice carrying human pHH can facilitate in vivo study of viral hepatitis infections ([@bib5], [@bib10]) and liver genetic diseases ([@bib6], [@bib43]), and the testing of small molecular drug candidates and biological components including antibodies ([@bib21]). Embryonic stem cell (ESC)- or iPSC-derived iHeps have been used to generate chimeric mice by engrafting them into the liver of non-obese diabetic severe combined immunodeficient (NOD-SCID) mice ([@bib12]), *NOD*/*Lt-SCID*/*IL-2Rγ*^*−*/*−*^ (NSG) mice ([@bib23]), or uPA transgenic mice ([@bib3], [@bib10]), where iHeps showed further maturation and regeneration potential and displayed key activities of primary hepatocytes. Our study has produced a mouse model that lacks the gene (*Ldlr*) involved in a human disease (FH) and is engrafted with patient-specific iHeps to mimic the specific human disease condition and perform in vivo drug testing. This approach has significant advantages over studies using *Ldlr* knockout mice alone ([@bib18]), as endogenous hepatocytes in the latter mouse model are not responsive to drugs modulating the LDLR pathway. A recent study showed engraftment of FH patient-specific iHeps injected subcutaneously rather than into the liver parenchyma of *Rag1*^*−*/*−*^/*Ldlr*^*−*/*−*^ mice, but the authors did not perform an assay to demonstrate functional recovery ([@bib26]). Another report demonstrated the feasibility of directly engrafting FH (due to compound heterozygosity in *LDLR* gene) pHH into *Fah*^*−*/*−*^/*Rag2*^*−*/*−*^/*Il2rg*^*−*/*−*^ mice, and the phenotype of FH was successfully rescued by *LDLR* gene therapy using adeno-associated virus ([@bib6]). Because of the lack of *Fah*, these mice had higher repopulation efficiency (\>70%) ([@bib6]) than our mice. However, a problem of this approach is that a population of mouse hepatocytes with intact LDLR remains while the engrafted patients\' pHH did not contain functional LDLR, which can be confounding factors when performing in vivo testing of drugs acting on the LDLR pathway. Moreover, primary FH hepatocytes are difficult to obtain and cannot be expanded in vitro. Although liver repopulation in our chimeric mice is significantly lower than for *Fah*^*−*/*−*^/*Rag2*^*−*/*−*^/*Il2rg*^*−*/*−*^ mice engrafted with pHH ([@bib2], [@bib6]), it is comparable with results of recent reports describing NSG mice or Gunn rats (a model of Crigler-Najjar syndrome 1) engrafted with iPSC-derived iHeps (2%--17% \[[@bib23]\] and 5.1% \[[@bib13]\]). In the future, crossing our *LRG* mice with *Fah* knockout mice could help achieve higher liver chimerism, and thus further upgrade in vivo drug testing studies using engrafted FH iHeps. It should also be considered that mice and humans bear differences in lipoprotein metabolism, and therefore it may be desirable to genetically engineer other mammalian species (e.g., rabbits) ([@bib31]) for more accurate studies using transplanted human FH iHeps. Nevertheless, despite the physiological differences between mice and humans and the moderate chimerism of our own model, the lowering of plasma LDL-C achieved with LDLR-competent iHeps was significant, while FH iHeps were less effective but exhibited good response to statins and particularly to PCSK9 antibodies. Besides plasma LDL-C levels, we measured endothelial function in aortas of *LRG* mice to assess the efficacy of engrafted iHeps and these two medications in vivo, as this parameter is affected early in patients with FH ([@bib40]). Our results showed that cell therapy and the two medications could improve EDV in chimeric mice, indicating that endothelial function can be used as a parameter to evaluate disease progression during preclinical testing in chimeric *LRG* mice or other similar animal models. Importantly, we also noticed that the engrafted iHeps could be maintained in *LRG* mouse liver, and were functional, for at least 3 months. Overall, these results highlight the potential relevance of transplanting iPSC-derived iHeps for the treatment of hereditary metabolic liver disorders ([@bib9]), and the use of chimeric animals humanized with disease-specific iHeps for preclinical evaluation of novel therapies. However, the long-term therapeutic efficacy of iPSC-based approaches remains unclear, and future studies are necessary to address this as well as safety concerns.

In summary, our work provides a state-of-the-art in vitro and in vivo platform for testing drugs and experimental cell therapies using FH iHeps. Similar platforms using other gene knockout mice and alternative patient-specific iHeps may be useful to investigate pathological mechanisms and perform preclinical studies for unrelated inherited liver diseases.

Experimental Procedures {#sec4}
=======================

DNA Sample Preparation and Sequencing {#sec4.1}
-------------------------------------

Genomic DNA was extracted from blood of subjects with FH using the QIAamp DNA blood kit (Qiagen). All exons of the *LDLR* gene locus were sequenced by Sanger sequencing, and mutations were identified by aligning with the reference sequence GenBank: [NM_000527.4](ncbi-n:NM_000527.4){#intref0010} from NCBI.

Cell Culture and Reprogramming {#sec4.2}
------------------------------

Urinary cells were obtained and expanded according to our published protocol ([@bib47]) with approval from the Institutional Review Board (HKCTR-725, <http://www.hkclinicaltrials.com>). Written informed consent from all patients is available upon request. Cells were reprogrammed with episomal vectors (Addgene) that encode human *OCT4*, *SOX2*, *KLF4*, *MYC*, *LIN28*, and *SV40LT* ([@bib41]), using a previously reported protocol ([@bib42]) with the combination of small molecular compounds containing 0.5 μM PD0325901 (Stemgent), 3 μM CHIR99021 (Stemgent), 0.5 μM A-83-01 (Stemgent), 1,000 U/mL human LIF (Millipore), 10 μM Y27632 (Sigma-Aldrich), and 100 ng/mL basic fibroblast growth factor (Peprotech). Human ESC-like colonies were picked at around day 25 and expanded in mTeSR1 (StemCell) on Matrigel (Corning)-coated plates with Accutase (Sigma-Aldrich).

Knockout Cell Line Generation {#sec4.3}
-----------------------------

Sigma-Aldrich donated the *LDLR* ZFNs. *LDLR*-ZFN mRNAs were generated through in vitro transcription of *LDLR*-ZFN plasmids with a MessageMAX T7 ARCA-Capped Message Transcription Kit (Cambio) according to the manufacturer\'s specifications. The parental iPSC clone was reported previously (UC C0406-iPS C4) ([@bib46]). Detailed procedures are described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

In Vitro Differentiation of iPSCs into iHeps {#sec4.4}
--------------------------------------------

Human iPSCs were differentiated into iHeps as reported previously ([@bib19]) but with small modifications at the endoderm induction stage: RPMI-1640 containing 100 ng/mL activin A (PeproTech) and 25 ng/mL WNT3a (R&D Systems) was employed for 1 day when the iPSCs had reached around 70% confluence, after which WNT3a was omitted from the medium for the following 2 days. HGF was purchased from PeproTech, Oncostatin M from R&D Systems, RPMI-1640, KnockOut DMEM, KnockOut Serum Replacement, and GlutaMAX Supplement from Life Technologies, DMSO from Sigma-Aldrich, and the HCM Bullet Kit from Lonza.

hALB, TC, and APOB Measurements {#sec4.5}
-------------------------------

hALB, TC, and APOB measurements were performed on supernatants of day-17 to -18 (24-hr interval) iHeps culture by ELISA using a kit (Cell Biolabs for hALB and TC; MABTECH for APOB), in 96-well assay plates according to the manufacturer\'s specifications.

LDL Uptake Assays {#sec4.6}
-----------------

LDL uptake assays employed fluorescently labeled LDL and 3,3′-dioctadecylindocarbocyanine (DiI)-LDL (Life Technologies), which were measured by microscopy or flow cytometry. Detailed procedures are described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

PCSK9 Antibodies and Simvastatin Treatments In Vitro {#sec4.7}
----------------------------------------------------

iPSCs were split onto 48-well plates and differentiated into iHeps as described above. At days 17--21 of differentiation, iHeps were treated with simvastatin and/or PCSK9 monoclonal antibodies (Cayman Chemical) for 16 hr and then incubated with 5 μg/mL DiI-LDL for 1 hr. Cells were washed with Ca^2+^/Mg^2+^-free PBS (CMF-PBS, Hyclone) and the DiI-LDL signal was captured with a CLARIOstar microplate reader (BMG LABTECH). Cells were then fixed with 4% paraformaldehyde and stained with ASGPR antibodies (Santa Cruz Biotechnology). Signal was read again with the microplate reader. Fluorescence signals were analyzed by MARS Data Analysis Software and normalized by the number of iHeps indicated by the ASGPR signal. Relative fluorescence units refer to the fold change of fluorescence values compared with the baseline (null treatment).

Chimeric Mice Generation {#sec4.8}
------------------------

The animal study was approved by the Institutional Review Board (CULATR-2592-11 and 3003-13). *Ldlr*^--/--^ mice (B6.129S7-*Ldlr*^*tm1Her*^/J, The Jackson Laboratory) were crossed with *Rag2*^−/−^/*Il2rg*^--/--^ mice (available in our lab by crossing of B6(Cg)-*Rag2*^tm1.1Cgn^/J mice with B6.129S4-*Il2rg*^tm1.wWjl^/J mice purchased from The Jackson Laboratory) to generate *LRG* mice. Genotype was confirmed by PCR and sequencing using genomic DNA from mouse ear. As recipient for iHeps, we used 8- to 16-week-old *LRG* mice. Mice were irradiated with 3 Gy of γ-ray using a Gammacell 3000 Elan II (MDS Nordion) machine 24 hr prior to cell engraftment. A total of 10^6^ iHeps or pHH (Lonza) suspended in 50 μL of 5.1 mg/mL Matrigel (Basement Membrane Matrix, Corning 354234) in CMF-PBS solution were engrafted into mouse liver by intrasplenic injection.

In Vivo Drug Testing {#sec4.9}
--------------------

For the HFHC diet group, mice were fed with HFHC diet from 7 days prior to engraftment. For the drug treatment group, drugs were administered from 7 days post-engraftment. The clinical-grade PCSK9 monoclonal antibody formulation alirocumab (*SAR236553*/REGN727, Sanofi and Regeneron Pharmaceuticals) was injected subcutaneously (10 mg/kg/week) with or without simvastatin (Zocor; Merck Sharp & Dohme) treatment (10 mg/kg/day in drinking water) for 21 days. Blood samples were collected from the facial vein at the indicated time points and the day of engraftment of iHeps was set as day 0 or baseline. Plasma LDL-C level was evaluated using an L type LDL-C detection kit (Wako). Functional studies of EDV in response to ACh were performed in aortas precontracted with phentolamine using a myograph (Danish Myo Technology) as previously reported ([@bib38]). Detailed procedures are described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistical Analyses {#sec4.10}
--------------------

Results are represented as the mean ± SEM unless otherwise indicated. Statistical analysis was performed with one-way or two-way ANOVA implemented in Prism 6 (version 6.03), or with Kruskal-Wallis test implemented in Scipy (version 0.18.1). All statistical tests were evaluated at a significance level of p \< 0.05.
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![Generation of a Panel of FH iPSCs\
(A) Family tree of WT and FH patients. Asterisk indicates patient-specific iPSCs generated in this study.\
(B) Schematic depicting the genomic region of *LDLR* mutations in FH iPSCs. The boxed area indicates the position of heterozygous duplicate of "TGCTGGC" in FH-1 iPSCs.\
(C) Western blotting shows LDLR levels in HepG2 cells (control) and iPSCs. ACTIN was used as loading control.\
(D) Genotype of a panel of FH isogenic knockout iPSC clones. Red labels the interval of both ZFN-recognized fragments; black in lowercase among the red indicates insertion that resulted in frameshift.\
(E) Phase contrast and immunofluorescence for ASGPR and A1AT of iHeps at day 17 of differentiation. Scale bars represent 50 μm.\
(F) Bar graph shows the percentage of ASGPR^+^ iHeps obtained with our differentiation protocol as measured by flow cytometry. A representative experiment with samples measured in triplicate is shown; error bars indicate SD.](gr1){#fig1}

![PCSK9 Antibodies Have a Stronger Effect than Statins on LDL Uptake by FH iHeps In Vitro\
(A) Micrographs show co-localization of fluorescently labeled LDL (green) and HNF4A (red). Scale bars represent 50 μm.\
(B) Left panel: bar graph shows percentage of DiI-LDL capture by flow cytometry in ASGPR^+^ iHeps with or without simvastatin. Statistical tests were performed with three independent experiments; p values are indicated on the graph and were obtained using two-way ANOVA adjusted with Tukey\'s multiple comparison. Error bars indicate SEM. Middle and right panels: bar graphs show concentration of TC and APOB secretion in iHeps culture as determined by ELISA; values were normalized by the concentration of secreted hALB. Statistical tests were performed on three independent experiments; p values are indicated on the graphs and were obtained using a Kruskal-Wallis test; error bars indicate SEM. Vehicle: DMSO.\
(C) Western blotting shows that PCSK9 is induced by simvastatin in iHeps.\
(D) LDL uptake capacity of healthy and heterozygous FH iHeps was measured with microplate readers and indicated as relative fluorescence units. Cells were treated with simvastatin and/or PCSK9 antibodies for 16 hr on days 17--21 of differentiation. Statistical tests were performed on three independent cell lines for both healthy (+/+, WT iHeps, and iHeps from another unaffected FH family member) and heterozygous FH iHeps (+/−, FH-1, and FH-2 iHeps). p Values are indicated on the figure and were obtained using one-way ANOVA adjusted with Dunnett\'s multiple comparison; error bars indicate SEM.](gr2){#fig2}

![Generation of Chimeric Mice Engrafted with FH iHeps\
(A) Schematic view of derivation of *LRG* mice.\
(B) Strategy for generation of FH chimeric mice, and assessment of LDL-C level and endothelial function.\
(C and D) Immunohistochemical staining for LDLR, hNA, and hALB in *LRG* mouse liver repopulated with the indicated iHeps or Matrigel (vehicle). Zoomed images for LDLR and hNA are shown. Scale bars represent 50 μm (C) and 200 μm (D).\
(E and F) Whole-slide scan image (E) and snapshot images (F) of hALB staining in mouse liver repopulated with +/+ iHeps. The location of snapshot images in the whole section is shown in the corner. Scale bars represent 2 mm (E and top left image in F) and 400 μm (remaining three images in F).\
(G) Scatter diagram shows the percentage of engrafted hALB^+^ iHeps in *LRG* mouse liver calculated based on whole-slide scanning images. Each dot represents one mouse with no less than four sections analyzed. Error bars indicate SEM.\
(H) Bar graph shows the percentage of repopulated hNA^+^ iHeps in *LRG* mouse liver (n = 4, including sections of *LRG* mice engrafted with +/+ iHeps × 1, +/− iHeps × 2, and −/− iHeps × 1); quantification of hNA^+^ cells was performed by manual counting (see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for detailed description). Error bars indicate SEM.\
(I) Plasma LDL-C levels in *LRG* mice engrafted with the indicated iHeps under normal diet (left panel) and HFHC diet (right panel) assessed at the indicated time points after iHep transplantation; n indicates number of mice. p Values are indicated on the figure and were obtained using a Kruskal-Wallis test; error bars indicate SEM.\
(J) Percentage change of plasma LDL-C from baseline at weeks 1, 4, 8, and 12 post-transplantation in *LRG* mice fed with HFHC diet and engrafted with +/+ iHeps or pHH; n indicates number of mice. p Values are indicated on the figure and were obtained using a Kruskal-Wallis test; error bars indicate SEM.\
(K) Immunohistochemical staining for hALB and hNA in *LRG* mouse liver repopulated with +/+ iHeps and pHH 12 weeks post-engraftment. Scale bars represent 200 μm.](gr3){#fig3}

![In Vivo Drug Testing with FH Chimeric Mice\
(A) Strategy for in vivo drug testing using *LRG* mice engrafted with FH iHeps.\
(B--D) Percentage change of plasma LDL-C from baseline at the indicated time points after iHep transplantation in *LRG* mice fed with HFHC diet and treated with simvastatin and/or PCSK9 antibodies; n indicates number of mice. p Values are indicated on the figure panel and were obtained using a Kruskal-Wallis test and error bars indicate SEM.](gr4){#fig4}

![Alirocumab and Statins Improve EDV in Chimeric *LRG* Mice\
(A and B) EDV in response to cumulative concentrations of acetylcholine (ACh) (A) and endothelium-independent vasodilation to sodium nitroprusside (SNP) (B) in aortas (precontracted with phentolamine \[Phe\]) from *LRG* mice fed with HFHC diet. Mice were engrafted with the indicated iHeps or vehicle; n indicates number of mice. p Values are indicated on the figure and were obtained using two-way ANOVA adjusted with Dunnett\'s multiple comparison; error bars indicate SEM.\
(C--F) EDV in response to ACh in aortae (precontracted with Phe) from *LRG* mice fed with HFHC diet. Mice were engrafted with the indicated iHeps and treated with simvastatin (daily) and/or alirocumab (weekly); n indicates number of mice. p Values are indicated on the figure and were obtained using two-way ANOVA adjusted with Dunnett\'s multiple comparison; error bars indicate SEM.](gr5){#fig5}
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